35.80
-0.27(-0.75%)
Currency In USD
| Previous Close | 36.07 |
| Open | 35.46 |
| Day High | 35.98 |
| Day Low | 34.08 |
| 52-Week High | 38 |
| 52-Week Low | 24.05 |
| Volume | 8.33M |
| Average Volume | 3.72M |
| Market Cap | 15.48B |
| PE | 15.63 |
| EPS | 2.29 |
| Moving Average 50 Days | 36.33 |
| Moving Average 200 Days | 32.36 |
| Change | -0.27 |
If you invested $1000 in Royalty Pharma plc (RPRX) since IPO date, it would be worth $887.24 as of September 09, 2025 at a share price of $35.8. Whereas If you bought $1000 worth of Royalty Pharma plc (RPRX) shares 3 years ago, it would be worth $871.89 as of September 09, 2025 at a share price of $35.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 04, 2025 8:15 PM GMT
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
GlobeNewswire Inc.
Sep 03, 2025 12:30 AM GMT
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 4.450%
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
GlobeNewswire Inc.
Sep 02, 2025 11:15 AM GMT
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treat